Strong growth, integration questions — Q1 sets FY27 tone amid Agarwal's Eye Hospital merger
On-plan growth expected at 20%+, with profitability tracking prior guidance; merger integration and GST headwind demand close watching.
The setup: momentum into integration
Dr. Agarwals enters Q1 FY27 riding strong fundamentals. FY26 closed with revenue of ₹2,080 Cr (+21.6% YoY), EBITDA at ₹614 Cr (+22.2%), and PAT at ₹168 Cr (+52.4%) — profit growth outpacing sales and earnings delivery ahead of expectations. Q4 alone showed revenue of ₹564 Cr (+22.6% YoY) and margins at 30.2%, signalling sustained pricing power and operational leverage into the new financial year.
The Street is uniformly bullish. Five analysts surveyed offer a consensus buy rating with an average 12-month price target of ₹545 (13.7% upside from ₹482 today), reflecting confidence in the growth trajectory and strategic positioning. FY27 is forecast to deliver revenue growth of 18.7% and earnings growth of 31.2% on an annualised basis, though Q1 specifics will set the tone for how aggressively the company can scale operations without margin erosion.
~₹510–550 Cr
~20–22% growth; Q4 FY26 revenue ₹564 Cr provides baseline; Q1 typically 23–26% of annual run
~28–30%
FY26 achieved 28.9%; Q4 expanded to 30.2%; merger integration costs may pressure mid-range
~15–20% YoY
FY26 PAT surged 52.4%, but on a normalised base (Q4 +17.4%); guidance will clarify run-rate
60 new centers planned
FY26 added 57 centers (323k surgeries); FY27 pace is accelerating; integration may affect Q1 ramp
What strong vs. weak looks like
Strong print: Revenue at or above ₹530 Cr with EBITDA margins holding 29%+ (PAT ₹75–82 Cr+); commentary on merger synergies and facility-opening velocity; full-year guidance maintained or raised. This would signal zero merger disruption and confidence in the 60-center plan. Weak print: Revenue miss (sub-₹500 Cr), margin compression below 28% due to one-time merger costs, or delayed facility openings. Any GST resolution update (positive or negative) could move the dial materially; the ₹20.5 Cr show-cause is an overhang until addressed.
On track with guidance?
The company has not delivered Q1-specific guidance, but the FY27 forecast of 18.7% revenue growth and 31.2% earnings growth is ambitious but defensible given Q4's +22.6% revenue pace. For Q1 to land on the 18–20% range would be conservative relative to the recent run; the real risk is whether margin expansion (the +22.2% EBITDA beat in FY26) can persist when merger integration is underway. Watch the management commentary on (a) one-time integration charges, (b) facility-opening ramp profile, and (c) any pressure from the GST notice's legal/tax reserves.
Since last quarter: the corporate scorecard
1 · NCLT-approved merger with Dr. Agarwal's Eye Hospital (May 11, 2026)
Secured and unsecured creditors approved the Scheme of Amalgamation on July 2, 2026. Integration begins immediately; expect management to detail facility consolidation, staff rationalisation, and synergy timelines on the call. This is the biggest structural event of the year.
2 · GST show-cause notice ₹20.5 Cr (May 20–21, 2026)
Notice alleges FY24 discrepancies. A follow-up notice of ₹15.08 Cr arrived earlier (May 15, 2026). Management will likely address quantum, timeline for resolution, and provisioning. This is a near-term legal overhang but unlikely to be material to FY27 guidance if historical GST cases trend.
3 · Subsidiary investment (May 26, 2026)
Orbit Healthcare Services (Mauritius) invested USD 200k in Orbit Health Care ETH PLC. Minor strategic move; routine international structuring. No P&L impact expected.
4 · Facility expansion tracking on plan
57 centers added in FY26 (323k surgeries performed). FY27 target: 60 new centers. Q1 typically sees lower facility openings (holiday/summer impact); watch for confirmation of Q1 opening count and capex spend rate.
The close: three things to watch
Dr. Agarwals reports Q1 FY27 results tomorrow (Aug 4) with revenue and profit growth likely to track 20%+ and the Street's expectations, but three vectors will determine how the print is received:
1 · Merger integration commentary
Zero mention of delays, facility consolidation timelines, and synergy milestones (cost saves, volume steps) will worry investors that integration has stalled. Look for guidance on merged-entity PAT contribution and full-year accretion.
2 · Margin trajectory and one-time costs
EBITDA margins above 29% with a clear breakdown of any integration-related non-recurring spend will support the narrative. Below 28% or vague on one-timers will raise questions about FY27 guidance credibility.
3 · GST resolution roadmap
Any update on the ₹20.5 Cr notice—settlement discussions, appeal filing, or provisioning call—will reduce legal overhang. If silent, assume worst-case reserve and reconcile to PAT.
Dr. Agarwals is fundamentally sound: a 20%−growing healthcare operator with expanding margins, strong ownership (FII 57.9%), and a clear M&A catalyst in the Agarwal's Eye Hospital merger. The Street is priced for success; consensus ₹545 target implies confidence in execution. Q1 will show whether the growth trajectory holds and the merger is accretive from day one or requires digestion. Revenue on-plan at ₹510–550 Cr is the floor; the test is margin hold (29%+) and management's conviction on the full-year 18.7% revenue and 31.2% earnings growth guidance. Watch the call for clarity on merger timing, synergy realisation, and GST resolution.
Informational and educational content only. Not investment advice.